[144] Guardant Health, Inc. SEC Filing

Rhea-AI Filing Summary

This Form 144 notice records a proposed sale of 100 shares of Guardant Health, Inc. common stock through Charles Schwab & Co., Inc., with an aggregate market value of $6,584 and an approximate sale date of 09/02/2025. The filer reports acquiring the shares through restricted stock lapses: 34 shares on 06/12/2025 and 66 shares on 07/04/2025, both listed as equity compensation.

The filing also discloses sales by the same person within the past three months: 100 shares sold on 06/02/2025 for $4,166 and 3,337 shares sold on 06/13/2025 for $157,573. The notice includes a representation that the seller is not aware of undisclosed material adverse information about the issuer.

Positive

• Transparent disclosure of proposed sale details including broker, share count, and aggregate market value
• Acquisition method clarified as restricted stock lapses with dates and amounts provided
• Past three-month sales disclosed, enabling investors to track recent insider dispositions

Negative

• Recent substantial sale on 06/13/2025 of 3,337 shares for $157,573 could be viewed as notable insider liquidity

Insights

Securities Analyst

TL;DR Routine insider transaction notice showing recent restricted stock vesting and planned small sale; prior larger sale in June is disclosed.

The filing documents standard Rule 144 procedural steps for an insider or affiliate planning to sell recently vested restricted shares. The proposed transaction is small in this notice (100 shares, $6,584 market value) and arises from equity compensation events dated 06/12/2025 and 07/04/2025. Notably, the filer reported meaningful prior sales in June totaling 3,437 shares for $161,739 across two dispositions, which are disclosed as completed transactions. From a compliance and market-disclosure perspective, the form fulfills Rule 144 notice requirements and provides transparent tracking of recent insider liquidity events.

Corporate Governance Expert

TL;DR Disclosure aligns with Rule 144 obligations; raises standard governance considerations about insider selling cadence.

The form includes acquisition details (restricted stock lapses) and identifies the broker and planned sale date, meeting regulatory disclosure norms. The seller also certified absence of undisclosed material adverse information. While the document itself is procedural, the sequence of a larger sale on 06/13/2025 followed by additional sales and a planned sale may be of interest to governance reviewers assessing insider trading policies and trading-plan usage. The filing does not state any trading-plan dates or indicate reliance on Rule 10b5-1.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	100	6584.00	124705857	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/12/2025	Restricted Stock Lapse	GUARDANT HEALTH, INC.			34	06/12/2025	Equity Compensation
Common	07/04/2025	Restricted Stock Lapse	GUARDANT HEALTH, INC			66	07/04/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Meghan V. Joyce 3100 HANOVER STREET PALO ALTO CA 94304	Guardant Health, Inc.	06/02/2025	100	4166.00
Meghan V. Joyce 3100 HANOVER STREET PALO ALTO CA 94304	Guardant Health, Inc.	06/13/2025	3337	157573.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does this Form 144 filing for Guardant Health (GH) report?

It reports a proposed sale of 100 shares via Charles Schwab with an aggregate market value of $6,584 and acquisition details from restricted stock lapses.

When were the shares acquired that are being sold under this Form 144?

The shares to be sold were acquired upon restricted stock lapses on 06/12/2025 (34 shares) and 07/04/2025 (66 shares).

Were there any insider sales by the same person recently?

Yes. The filer sold 100 shares on 06/02/2025 for $4,166 and 3,337 shares on 06/13/2025 for $157,573.

Which broker is handling the proposed sale?

The broker listed is Charles Schwab & Co., Inc. located at 3000 Schwab Way, Westlake, TX 76262.

Does the filing state reliance on a Rule 10b5-1 trading plan?

No. The filing does not provide a date of plan adoption or indicate reliance on a Rule 10b5-1 trading plan.